Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
Key Details
- 1Lucida Medical, a UK-based AI firm, raised $11.4 million in new funding.
- 2Their Prostate Intelligence (Pi) software uses MRI to help diagnose prostate cancer.
- 3The software is already deployed in up to 15 UK NHS hospitals.
- 4NHS invested around $3 million to use the platform, aiming for diagnoses within 28 days.
- 5The new funds will help pursue US FDA regulatory approval and expand to detect other clinical conditions.
Why It Matters
This funding supports efforts to scale AI-powered prostate cancer diagnosis, addressing critical radiology workforce shortages and speeding up patient pathways. US FDA approval could open access to broader markets and bring innovative diagnostic AI tools to more clinicians and patients.
Source
Radiology Business
Related News
•AuntMinnie
Deep Learning Model Enhances MRI Detection of Brain Metastases
A deep learning model significantly improves speed and accuracy of brain metastasis detection on MRI scans.
•Radiology Business
Radiologists Push Back Against AI CEO's Claims of Specialty Replacement
Radiologists challenge Anthropic CEO Dario Amodei's assertion that AI has already replaced their core tasks.
•Cardiovascular Business
Radiology Leads in FDA-Cleared Imaging AI Algorithms, Cardiology Surges
Radiology maintains its lead as the specialty with the most FDA-cleared AI algorithms, while cardiology now surpasses 200 cleared tools.